Myxoinflammatory Fibroblastic Sarcoma of Eyeball in an Infant: A Rare Presentation

Jain, Ekta; Kini, Lata; Alaggio, Rita; Ranganathan, Sarangarajan

doi:10.1177/1066896919879497

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small number of cases also occur in children or adolescents, and tumors primarily arise in the soft tissue location of the distal part of the limb ( 1 , 7 ). In this study, we have summarized the clinicopathological features of MIFS reported in the literature in the rare sites (non-bone and soft tissue, since 1998) ( Table 2 ) ( 6 , 8 , 9 ). Clinically, MIFS may be similar to benign lesions and can be often misdiagnosed as the slippery membrane inflammation, ganglion cysts, or giant cell tumor of the tendon sheath.…”

Section: Discussionmentioning

confidence: 99%

Myxoinflammatory Fibroblastic Sarcoma of the Parotid Gland: First Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, low-grade malignant soft tissue tumor. Most of the previously reported cases about this tumor were diagnosed within the soft tissues. Here, we report a unique case of MIFS of the right parotid gland in a 39-year-old Chinese male. The tumor primarily consisted of an inflammatory area and a mucus-like area in a migratory distribution. A number of lymphocytes, neutrophils, viral-like cells with large nucleoli, and eosinophilic cytoplasm or Reed-Sternberg-like cells, as well as spindle cells and epithelial-like aberrant cells, were observed within the tumor. They were found to express Vimentin and CD10 protein and no other specific immunohistochemical markers. The various cytomorphology and immunohistochemical features of this tumor were highly consistent with MIFS found in other sites. Therefore, several leading pathologists ultimately confirmed the final diagnosis of MIFS in the right parotid gland after repeated deliberation. To our knowledge, this is the first case of MIFS occurring in the parotid gland. Thus, our study provides a novel basis for identifying the biological behavior of the tumor in MIFS and also allows us to better understand the pathology of this rare tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Myxoinflammatory Fibroblastic Sarcoma of the Parotid Gland: First Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It often manifests as a painless mass at the distal end of the limb, primarily on the hands and feet, accounting for almost two-thirds of all cases. [4] However, it can occur in multiple body parts, including the iris, [5] parotid gland, [6] maxilla, [7] back, [8] eyeball, [9] nasal dorsum, [10] scalp, [11] and groin. [12] As a result, the World Health Organization (WHO) renamed it myxoinflammatory fibroblastic sarcoma (MIFS) in 2002.…”

Section: Introductionmentioning

confidence: 99%

Myxoinflammatory fibroblastic sarcoma of the liver: Case report and literature review

Li,

Zhang,

Zheng

et al. 2024

Medicine

View full text Add to dashboard Cite

Rationale: Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare low-grade malignant soft tissue sarcoma that primarily affects the distal extremities in adults, with the highest incidence in patients in their 40s and 50s. It has a high local recurrence rate and a low metastasis rate. Although MIFSs have been documented in other sites, an MIFS in the liver is highly unusual. Herein, we present a case of a patient with hepatic MIFS. Patient concerns: The patient was a 58-year-old Chinese man with abdominal pain as the primary symptom. Abdominal computed tomography and magnetic resonance imaging revealed a mass in the right posterior lobe of the liver. The patient underwent surgical excision, and the excised specimen was identified as MIFS. Three years later, the patient returned to our hospital for abdominal pain. Computed tomography and magnetic resonance imaging revealed a mass in liver segments 2/3/4. Diagnosis: Postoperative pathological examination of the tumor revealed the recurrence of MIFS. Interventions: The patient underwent surgical resection of the MIFS. Outcomes: The patient received multiple pirarubicin-based chemotherapy treatments and an ALK inhibitor (anlotinib) within 6 months after surgery, but the tumor recurred. Lessons: MIFS can not only occur in the proximal limbs, trunk, head, and neck but can also affect the abdominal organs. Surgical resection remains the primary treatment option for MIFS in the absence of any contraindications. Because the recurrence rate of MIFS is high, meticulous long-term monitoring is required.

show abstract